2026-01-27T10:28:48-06:00 2025-03-31 541342298 Kositzka Wicks and Company 5270 Shawnee Road Suite 250 Alexandria VA 22312 990 2024-04-01 202510044 The Side-Out Foundation SIDE 8773447465 11208 Waples Mill Road 103 Fairfax VA 22030 Rick Dunetz Executive Director 8773447465 2026-01-26 1 1 Jennifer S Manster CPA P01383338 7036422700 2024 2025-03-06 01:10:19Z Rick Dunetz 11208 Waples Mill Road 103 Fairfax VA 22030 1488321 0 X www.side-out.org X 2005 VA Making breast cancer a manageable disease (similar to diabetes) takes an organization with extraordinary vision & cutting-edge tactics. The Side-Out Foundation is a 501(c)(3) non-profit organization, founded in 2004 by Richard and Bryant Dunetz, to empower a new generation of advocates, make significant and identifiable impact on the way breast cancer is treated, and give those living with metastatic breast cancer (MBC) more tomorrows.Since its inception, the foundation has (I) built educational and community-driven programs focused on teaching advocacy to the next generation of changemakers, equipping them with skills and tools to support Side-Out's mission, as well as any cause they wish to connect to in their future; (II) forged groundbreaking collaborations with prestigious research teams, hospitals, and research centers nationwide and; (III) leveraged new technologies to improve, alter cancer trajectories, and constantly challenge the foundation of cancer care. 4 3 7 0 0 0 1306378 1416040 0 0 46980 52869 8111 10061 1361469 1478970 4345 0 0 0 549462 776542 0 0 155590 635190 866415 1188997 1642957 172472 -163987 2115644 2106993 246571 401907 1869073 1705086 X See Schedule O. 0 0 1232025 During the 20242025 fiscal year we achieved the following research objectives.1. Publication in the British Journal of Cancer. Our manuscript, "Functional activation of the AKTmTOR signalling axis in a real-world metastatic breast cancer cohort" by Rasad D, Baldelli E, Blais EM, Davis J, El Gazzah E, Mueller C, Gomeiz A, Ibrahim A, Newrekar AV, Corgiat BA, Dunetz R, Petricoin III EF, Wei Q, and Pierobon M, was published in the British Journal of Cancer (Br J Cancer. 2024 Nov;131(9):1543-1554). This study analyzed a real-world cohort of 171 metastatic breast cancer patients who underwent multi-omic profiling through Perthera. The primary objective was to characterize metastatic lesions from a genomic perspective and compare them with historical cohorts of primary tumors, with a particular focus on how genetic alterations in the AKTmTOR pathway translate into phenotypic changes at the protein level. The findings represent an important step forward for precision medicine and demonstrate the superiority of multi-omic approaches in identifying patients who may respond to inhibitors targeting the AKT-mTOR pathway. In addition, the study further validated that increased activation of AKT downstream substrates is associated with response to CDK4/6 inhibitor therapy, consistent with observations from the Side Out 3 clinical trial (NCT03195192).2. Discovery of a novel protein-protein interaction with therapeutic relevance. We identified a previously uncharacterized protein-protein interaction that represents a new druggable axis and a potential predictor of response to CDK4/6 inhibitors combined with endocrine therapy in metastatic breast cancer. This discovery emerged from preclinical studies conducted at George Mason University and resulted in the submission of a provisional patent application for the development of a novel diagnostic test to guide patient allocation to targeted treatments. 1232025 1 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 7 1 0 0 0 0 0 0 0 0 0 0 0 0 X 4 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 1 1 0 AL AR CA FL GA IL KS KY MD MA MI MN MS NH NJ NY NC OH OK PA RI SC UT VA WV WY X Rick Dunetz 7036158740 11208 Waple Mill Rd 103 Fairfax VA 22030 Rick Dunetz Chief Vision Officer 40.00 X X 110434 0 5469 Gary Thompson Board chair 1.00 X X 0 0 0 Stephanie Reffey Director 1.00 X 0 0 0 Sharon Dingman Director 1.00 X 0 0 0 Ellen Dempsey Executive Director 40.00 X 149908 0 6663 260342 0 12132 2 0 1 0 George Mason University 4400 University Drive MSN 4C6 Fairfax VA 22030 Clinical Trial Support 303215 1 1416040 1416040 52869 52869 19412 9351 10061 10061 1478970 10061 0 52869 X 292671 172438 112125 8108 399306 339406 39935 19965 9079 7717 908 454 20496 17273 2211 1012 54990 40833 11913 2244 27736 19415 8321 223335 178468 4921 39946 115401 23080 26253 66068 7310 7310 10220 8176 1533 511 61554 49243 9233 3078 34591 31647 2944 2412 2171 241 3782 3782 Clinical trial 309215 309215 Subscriptions 31758 25407 4763 1588 Payroll expenses 17347 12881 3758 708 Utilities 6485 5188 973 324 15269 5100 9850 319 1642957 1232025 255342 155590 1868528 1920207 39268 32840 3795 3795 348 348 550594 542099 7103 8495 196602 141308 2115644 2106993 29889 25711 216682 376196 246571 401907 X 1869073 1705086 1869073 1705086 2115644 2106993 -163987 0 X 0 1 X 0 0 X 400020 1127967 1230616 1306378 1416040 5481021 7460 26778 13750 29814 19412 97214 407480 1154745 1244366 1336192 1435452 5578235 0 0 0 5578235 197 102 802 46980 52869 100950 197 102 802 46980 52869 100950 1200 1200 408877 1154847 1245168 1383172 1488321 5680385 0.98200 0.99100 0.01780 0.00880 X Schedule A, Part III, Line 12, Explanation of Other Income: Cashback rebates - 2020 Amount: $ 1,200. 1875 677 1198 31268 24045 7223 517451 517377 74 8495 Security deposit 5928 Operating right-of-use asset 135380 141308 Operating lease liabilities 155942 Clinical trial liabilities 220254 376196 X 1499830 20860 20860 1478970 0 1478970 1663817 20860 20860 1642957 0 1642957 Part X, Line 2: The Foundation is exempt from federal income tax as a nonprofit organization described in Section 501(c)(3) of the Internal Revenue Code and is classified as an organization other than a private foundation. The Foundation did not have a liability for unrelated for unrelated business income for the year ended March 31, 2025. X X 0 0 0 0 0 0 0 1 0 Ellen Dempsey Executive Director 149908 0 0 0 0 0 4500 0 2163 0 156571 0 0 0 Part I, Line 7 The Chief Vision Officer received a bonus based on a performance evaluation by the Board of Directors Form 990, Part VI, Section B, line 11b The Executive Director and Secretary review the return. Form 990, Part VI, Section B, line 12c Written conflict of interest policy is in place and monitored at all levels of the organization. Form 990, Part VI, Section B, line 15 The Board reviews and approves compensation for all leadership positions. Form 990, Part VI, Section C, line 19 No other documents are available to the public. Form 990, Part IX, line 11g Website and software services: Program service expenses 24,910. Management and general expenses 4,672. Fundraising expenses 1,557. Total expenses 31,139. Consultants: Program service expenses 153,558. Management and general expenses 249. Fundraising expenses 38,389. Total expenses 192,196.